Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose

Hepatology

Volumn 24, Issue 1, 1996, Pages 21-26

  Shiffman, Mitchell L ^a   Hofmann, Charlotte M ^a   Luketic, Velimir A C ^a   Sanyal, Arun J ^a   Contos, Melisa J ^a   Mills, A Scott ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 0029889098     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008707264     Document Type: Article

References (27)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial. N Eng J Med 1989;321:1501-1506.
2. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
3. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 mU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
4. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha interferon. HEPATOLOGY 1992; 15:1013-1016.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Eng J Med 1995;332:1457-1462.
6. De Medina M, Schiff ER, Hepatitis C: Diagnostic assays. Semin Liv Dis 1995;15:33-40.
7. Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. HEPATOLOGY 1994;19:1342-1346.
8. Peters M. Mechanisms of action of interferons. Semin Liv Dis 1989;9:235-239.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
10. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987;56:727-777.
11. Kirchner H. Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984;7:347-374.
12. Yap WH, Teo TS, Tan YH. An early event in the interferon-induced transmembrane signaling process. Science 1986;234:355-358.
13. Gariglio M, Franco A, Cavallo G, Landolfo S. Evidence for a GTP-binding protein involved in interferon-gamma transduction signal. J Interferon Res 1988;8:463-472.
14. Baglioni C, Maroney TA, West DK. 2′5′-oligo(A)polymerase activity and inhibition of viral mRNA synthesis in interferon treated HeLa cells. Biochemistry 1979;18:1765-1770.
15. Beresini MH, Lempert MJ, Epstein LB. Overlapping polypeptide induction in human fibroblasts in response to treatment with interferon-alpha, interferon-gamma, interleukin-alpha, interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor. J Immunol 1988;140:485-493.
16. Chen L, Mathieu-Mahul D, Bach FH, Dausset J, Bensussan A, Sasportes M. Recombinant interferon alpha can induce rearrangement of T cell antigen receptor alpha genes and maturation to cytotoxicity in T lymphocyte clones in vitro. Proc Natl Acad Sci U S A 1986;83:4887-4889.
17. Czaja AJ, Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci 1995;40:435-456.
18. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-523.
19. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose and combination with azathioprine compared. Gut 1975;16:876-883.
20. Pozzato G, Moretti M, Franzin F, Croce Ls, Tiribelli C, Masayu T, Kaneko S, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. Lancet 1991;338:509 [Letter].
21. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, Takayanasi M. Hepatitis C virus genotypes are not responsible for the development of serious liver disease. Dig Dis Sci 1994;39:234-239.
22. Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, Fusamoto H, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994;21:468-473.
23. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liv Dis 1995;15:41-63.
24. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B hepatitis. Gastroenterology 1994;106:686-690.
25. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
26. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
27. 2b. HEPATOLOGY 1993;18: 1300-1305.